Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

Press/Media

Period10 Dec 2024

Media coverage

8

Media coverage

  • TitleGeron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date10/12/24
    URLct.moreover.com/?a=55512581046&p=1gw&v=1&x=fm_u3BCVVSY1jCktIY0u7g
    PersonsJohn Mascarenhas
  • TitleGeron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO(TM) (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date10/12/24
    PersonsJohn Mascarenhas
  • TitleGeron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletADVFN UK
    Country/TerritoryUnited Kingdom
    Date10/12/24
    URLct.moreover.com/?a=55512533194&p=1gw&v=1&x=jN7Dsx8GzrMoVgCUA3XyxA
    PersonsJohn Mascarenhas
  • TitleGeron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletStockTitan.net
    Country/TerritoryUnited States
    Date10/12/24
    URLct.moreover.com/?a=55512562217&p=1gw&v=1&x=j4zJjPE6cNY47kr1CkllcA
    PersonsJohn Mascarenhas
  • TitleGeron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletYahoo! Finance
    Country/TerritoryUnited States
    Date10/12/24
    URLct.moreover.com/?a=55512668635&p=1gw&v=1&x=jy3-Ml1du-YQAsOjXc7Fzw
    PersonsJohn Mascarenhas
  • TitleGeron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELOtm (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletLe Lezard.com
    Country/TerritoryCanada
    Date10/12/24
    URLct.moreover.com/?a=55512618743&p=1gw&v=1&x=lxL6pXHYGguZRrDLRwUltA
    PersonsJohn Mascarenhas
  • TitleGeron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO(TM) (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletStockwatch
    Country/TerritoryCanada
    Date10/12/24
    URLct.moreover.com/?a=55512624433&p=1gw&v=1&x=3seYHHzeg3V_g0hQt5KzDQ
    PersonsJohn Mascarenhas
  • TitleGeron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletCrwe World
    Country/TerritoryUnited States
    Date10/12/24
    URLct.moreover.com/?a=55512723936&p=1gw&v=1&x=GTxolq99-6IqZgb7lhVVSw
    PersonsJohn Mascarenhas